Aspira Women’s Health Announces Dr. Jody Berry as New Chief Scientific Officer
Retrieved on:
Monday, September 11, 2023
Department of Medical Microbiology (Schering AG), Abstract, Pelvic inflammatory disease, Bachelor of Science, University, Apotex, Medical microbiology, HIV, Cangene, HIV-1, Head, Monoclonal antibody, Public Health Agency of Canada, COVID-19, Woman, CIHR, Infection, Research, Lehigh University, American Biological Safety Association, National Microbiology Laboratory, University of Manitoba, Government, Immunochemistry, Chlamydia trachomatis, Philosophy, Outline, Gynaecology, Blood, Scripps Research, Protein engineering, R, Public Health Agency, G.H. Raisoni Department of Microbiology and Biotechnology, University Arena (Western Michigan University), Vaccine, Science, Chlamydia, Molecular biology, Aspira
AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.
Key Points:
- AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.
- Dr. Berry is a seasoned scientific leader with over two decades of commercial, government and academic experience.
- Jody is a dynamic leader with decades of experience launching disruptive products and building effective research and development teams,” said Nicole Sandford, Chief Executive Officer of Aspira.
- Dr. Berry is author or co-author on over 100 peer-reviewed published journal articles, abstracts, scientific posters, and monographs.